Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 8/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2169223 | 0.90 | EPHX2 (0.37) | RECQLEPHX2HTR1A | |
| SCHEMBL12013043 | 0.88 | RECQL (0.34) | RECQLCYP11B2DRD2DRD3PTPN11 | |
| SCHEMBL12013045 | 0.88 | RECQL (0.34) | RECQLCYP11B2DRD2DRD3PTPN11 | |
| SCHEMBL12012593 | 0.87 | RECQL (0.33) | RECQLCYP11B2DRD2DRD3PTPN11 | |
| SCHEMBL2169412 | 0.87 | RECQL (0.33) | RECQLCYP11B2DRD2DRD3PTPN11 | |
| SCHEMBL2169410 | 0.87 | RECQL (0.33) | RECQLCYP11B2DRD2DRD3PTPN11 | |
| SCHEMBL2171369 | 0.87 | RECQL (0.33) | RECQLCYP11B2DRD2DRD3PTPN11 | |
| SCHEMBL12012589 | 0.87 | RECQL (0.33) | RECQLCYP11B2DRD2DRD3PTPN11 | |
| SCHEMBL2168735 | 0.86 | HSD11B1 (0.39) | — | |
| SCHEMBL12012567 | 0.86 | HSD11B1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252781-B2 | 1,2-diazetidin-3-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-28 | — | — | US | claimed |
| EP-2348019-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2011-07-27 | — | — | EP | claimed |
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2010-06-10 | — | — | US | claimed |
| US-8252781-B2 | 1,2-diazetidin-3-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252781-B2 | 1,2-diazetidin-3-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252781-B2 | 1,2-diazetidin-3-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| EP-2348019-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| EP-2348019-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2010-06-10 | — | — | US | disclosed |
| WO-2010050191-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME | 興和株式会社 (JP) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144694-A1 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | HSD11B1, HSD11B2, HSD3B1 | RECQL 3061/4885CYP11B2 8/4885DRD2 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.